Form 4: Marker Therapeutics Director Katharine Knobil Granted Stock Options

Director Katharine Knobil received stock options for 30,000 shares of Marker Therapeutics, Inc. at an exercise price of $1.59 on February 12, 2025.

Summary

• Katharine Knobil, a director of Marker Therapeutics, Inc., was granted stock options on February 12, 2025.
• The options are for 30,000 shares of common stock.
• The exercise price of the options is $1.59 per share.
• The options were granted under the company's 2020 Omnibus Stock Ownership Plan.
• One-third of the shares vest on the first anniversary of the grant date, and the remainder vest in equal annual installments over the subsequent two years, contingent upon continued service as a director.
• The options expire on February 12, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The vesting schedule is standard, and the exercise price is defined. There is nothing particularly positive or negative about the announcement itself.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant.

Key Dates